Casi Pharmaceuticals is planning on significant manufacturing investments in China with a facility planned in Jiangsu Province, China. Case Pharmaceuticals (EntreMed) is based in Rockville, MD and appears to leverage resources and expertise in China to commercialize products in China and other markets. With a focus on oncology we include their pipeline. http://www.casipharmaceuticals.com/product-pipeline/
Their EVOMELA (melphalan) for injection, is already marketed in the U.S. by a partner and is intended to be used as a conditioning treatment prior to autologous stem cell transplant for patients with multiple myeloma. Their ZEVALIN product is marketed in the U.S. by partner. It is approved for patients with relapsed or refractory, low-grade or follicular B-cell non-Hodgkin’s lymphoma.